Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms BGB-B455 |
Target |
Action stimulants, modulators |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CLDN6 modulators(Claudin 6 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 18 Mar 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 18 Mar 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 18 Mar 2025 | |
| Metastatic Solid Tumor | Phase 1 | United States | 18 Mar 2025 | |
| Metastatic Solid Tumor | Phase 1 | China | 18 Mar 2025 | |
| Metastatic Solid Tumor | Phase 1 | Australia | 18 Mar 2025 | |
| Non-squamous non-small cell lung cancer | Phase 1 | United States | 04 Mar 2025 | |
| Non-squamous non-small cell lung cancer | Phase 1 | Australia | 04 Mar 2025 | |
| Ovarian Serous Tumor | Phase 1 | United States | 04 Mar 2025 | |
| Ovarian Serous Tumor | Phase 1 | Australia | 04 Mar 2025 |






